Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 13.70M P/E - EPS this Y - Ern Qtrly Grth -
Income -24.22M Forward P/E -15.50 EPS next Y - 50D Avg Chg -16.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -32.00%
Dividend N/A Price/Book 0.49 EPS next 5Y - 52W High Chg -77.00%
Recommedations 2.50 Quick Ratio 4.15 Shares Outstanding 14.20M 52W Low Chg 24.00%
Insider Own 14.99% ROA -48.80% Shares Float 187.84M Beta -0.04
Inst Own 24.96% ROE -91.02% Shares Shorted/Prior 221.87K/244.31K Price 1.24
Gross Margin - Profit Margin - Avg. Volume 183,688 Target Price -
Oper. Margin - Earnings Date May 9 Volume 27,795 Change -3.12%
About Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Chemomab Therapeutics Ltd. News
04/18/24 Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
04/02/24 Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
03/25/24 Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
03/07/24 Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update
03/05/24 Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference
02/20/24 Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases
02/14/24 Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update
02/05/24 Chemomab Therapeutics to Participate in Upcoming Investor Conferences
01/30/24 Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
01/03/24 Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024
11/16/23 Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis
11/15/23 Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis
11/13/23 Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting® 2023
11/09/23 Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
11/06/23 Chemomab Therapeutics Discloses Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement
10/30/23 Chemomab Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update
10/26/23 Chemomab Therapeutics to Present at Upcoming Scientific Conferences
09/28/23 Chemomab Therapeutics to Present Its CM-101 Clinical Program in Primary Sclerosing Cholangitis at 2023 Roth MKM Healthcare Opportunities Conference
08/29/23 Chemomab Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
08/14/23 Chemomab Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Corporate Update
CMMB Chatroom

User Image DLT4489 Posted - 13 hours ago

$CMMB exactly 🤣🤣👍👍

User Image Sandwichmaneuver Posted - 14 hours ago

$CMMB its green, which means there’s a 100% chance of it being red tomorrow 😂

User Image tushar0077 Posted - 16 hours ago

$CMMB

User Image DLT4489 Posted - 16 hours ago

$CMMB it dropped from 0.80 to 0.58, then jumped to 0.70 and you guys are happy?????? 🤣🤣🤣🤣🤣🤣🤣🤣🤣

User Image longjohntrader Posted - 17 hours ago

$CMMB let"s see...

User Image DLT4489 Posted - 19 hours ago

$CMMB company tries to prevent RS by doing $h!shows, but it's imminent be ready

User Image DLT4489 Posted - 19 hours ago

$CMMB what a great news, it was so attractive to investors🤣🤣 25k volume 💩💩💩🤣🤣🤣

User Image MUBSN Posted - 23 hours ago

$CMMB once we have volume, this will spike to 2 dollars at least. We only have to be in the loop of an institucional investor that wants to buy a small stake

User Image tushar0077 Posted - 1 day ago

$CMMB great PR. Should climb to $1 soon and further

User Image DLT4489 Posted - 1 day ago

$CMMB will be shorted soon.

User Image DLT4489 Posted - 1 day ago

$CMMB as always, I wouldn't be surprised if it closes Red big time

User Image DLT4489 Posted - 1 day ago

$CMMB no one buys this garbage because everyone knows they are lying and keep stealing money from investors for their research and pockets, otherwise it would be good volume.

User Image DLT4489 Posted - 1 day ago

$CMMB told you that expect a sh!!t show in April, more show coming

User Image DLT4489 Posted - 1 day ago

$CMMB seriously dude????? Unbelievable how you can be bullish on this garbage.

User Image shreyvakil Posted - 1 day ago

$CMMB amazing transformational results! 👏

User Image Stock_Titan Posted - 1 day ago

$CMMB Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis https://www.stocktitan.net/news/CMMB/chemomab-reports-new-peer-reviewed-publication-reinforcing-the-lp7sr6lx3kgf.html

User Image DLT4489 Posted - 1 day ago

$CMMB great 👍 action, let get 0.49 by Friday.

User Image DLT4489 Posted - 1 day ago

$CMMB ready for 0.59, 0.49, 0.39 and then 0.29??

User Image DLT4489 Posted - 1 day ago

$CMMB don't forget to follow @shreyvakil who's been bullish since $60. He knows a lot

User Image DLT4489 Posted - 1 day ago

$CMMB You never learn when it acts like this, means big 💩💩💩💩💩💩💩💩 coming I mentioned this before

User Image DLT4489 Posted - 1 day ago

$CMMB RS is coming, watch out

User Image DLT4489 Posted - 2 days ago

$CMMB You don't know what's coming 🤭🤭

User Image DLT4489 Posted - 2 days ago

$CMMB this will be kicked out hard by nasdaq soon. They deserve it, short it until then

User Image Kazinovsky Posted - 2 days ago

$CMMB I wrote to investors relation last week regarding delisting, they replied within hours with the following: We are taking the standard step of requesting an additional 180-day extension to regain compliance. We expect that this request will be granted, as we meet all the other listing requirements. The company looks forward to the readout of our topline data from the critical Phase 2 PSC trial in a few months' time, which could be transformational for Chemomab.

User Image Kazinovsky Posted - 2 days ago

$CMMB

User Image DLT4489 Posted - 2 days ago

$CMMB short this trash scam like other isr@eli scam companies.

User Image DLT4489 Posted - 2 days ago

$CMMB Told you, watch it for more f....g drop

User Image DLT4489 Posted - 3 days ago

$CMMB it's ready to be burned soon by RS, it's imminent

User Image DLT4489 Posted - 3 days ago

$CMMB Get ready for R/S, it's over. Funeral time ⏲️

User Image DLT4489 Posted - 3 days ago

$CMMB hey Adi mor, Ready for 69??? 🤣🤣🤣🤭🤭🤭

Analyst Ratings
Oppenheimer Perform Mar 8, 24
Roth MKM Buy Oct 6, 23
Oppenheimer Perform Jun 7, 23
Oppenheimer Outperform Apr 18, 23
Oppenheimer Outperform Mar 10, 22
Aegis Capital Buy Dec 7, 21
Cantor Fitzgerald Overweight May 26, 21
Oppenheimer Outperform May 7, 21
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Cohen Neil Harris Director Director Nov 16 Sell 2 2,409 4,818 10,000 11/18/22
Mor George Adi Chief Scientific Off.. Chief Scientific Officer Nov 16 Sell 2.08 582,023 1,210,608 257,247 11/17/22
Marvin Donald Executive VP, CFO &.. Executive VP, CFO & COO Mar 16 Buy 3.28 500 1,640 2,000 06/21/22
Maryles Joel Michael Director Director Mar 18 Buy 4.34 1,000 4,340 1,000 03/21/22
Marvin Donald Executive VP, CFO &.. Executive VP, CFO & COO Mar 14 Buy 4.04 1,250 5,050 1,500 03/21/22
Darvish Nissim Director Director Mar 11 Buy 4.28 1,200 5,136 1,200 03/14/22